Infliximab for the treatment of recalcitrant bullous Sweet syndrome in a 10-year-old girl.
acute febrile neutrophilic dermatosis
bullous Sweet syndrome
cardiovascular elastolysis
postinflammatory cutis laxa
Journal
Pediatric dermatology
ISSN: 1525-1470
Titre abrégé: Pediatr Dermatol
Pays: United States
ID NLM: 8406799
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
pubmed:
10
9
2020
medline:
15
5
2021
entrez:
9
9
2020
Statut:
ppublish
Résumé
We report the case of a 10-year-old girl with bullous Sweet syndrome, recalcitrant to high-dose systemic corticosteroids. Subsequent treatment with infliximab resulted in a rapid improvement in cutaneous lesions and systemic symptoms. Cutis laxa was noted in the healed skin. We propose early second-line treatment with infliximab in children with steroid-refractory Sweet syndrome.
Substances chimiques
Infliximab
B72HH48FLU
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1183-1184Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Lee GL, Chen AYY. Neutrophilic dermatoses: kids are not just little people. Clin Dermatol. 2017;35(6):541-554.
García-Romero MT, Ho N. Pediatric Sweet syndrome. A retrospective study. Int J Dermatol. 2015;54(5):518-522.
Halpern J, Salim A. Pediatric sweet syndrome: case report and literature review. Pediatr Dermatol. 2009;26(4):452-457.
Rochet NM, Chavan RN, Cappel MA, Wada DA, Gibson LE. Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. J Am Acad Dermatol. 2013;69(4):557-564.
Ma EH, Akikusa JD, MacGregor D, Ng J, Su JC. Sweet's syndrome with postinflammatory elastolysis and Takayasu arteritis in a child: a case report and literature review. Pediatr Dermatol. 2012;29(5):645-650.